Pemigatinib for Cancer

"A large percentage of people get some form of cancer at some point in time. Approximately 14.3% of men and 20.4% of women are found to have cancer at some point during their life. However, how many people get cancer a year in the United States is unknown. A good metric to use is to look at the average percentage of people with cancer per year per 10,000 in the general population. Then you just look at how many people get cancer during their lifetime. For example, there are approximately 2,622,000 people without cancer per year who do not get cancer." - Anonymous Online Contributor

"The risk of developing cancer is significantly increased if a patient has had cancer before, or their first-degree relative has had cancer or an organ-specific cancer. It has been shown that cancer cases were associated with cigarette smoking; excess risk did not seem to be related to age or alcohol consumption. In addition to the effects of environmental factors, individual susceptibility and the genetic predisposition to cancer are also strongly linked to increased risk. The risk of developing cancer is more important in smokers than non-smokers. The risk of developing cancer also appears to be increased by hereditary factors. Although cancers are not always benign, benign cancers have been linked to tobacco use. Some evidence exists linking schizophrenia with prostate cancer and thyroid cancer." - Anonymous Online Contributor

"There is no cure for cancer. If metastasis does not occur, then there is a possibility of curing the primary cancer. However, since metastasis still occurs, complete cure is not possible." - Anonymous Online Contributor

"Most people in the developed world are concerned about cancer and some spend substantial time attempting to minimize possible risk. While cancer has always been a major public health issue, it is becoming obvious that such concern has led to a decrease in survival, to a marked increase in death as compared with the past. It would be wise to accept that cancer is inevitable and that we must strive to live. The aim of health care systems should be to make the best of every opportunity to prolong life, by preventing disease and illness through health care education and prevention of lifestyle factors. If we do not do this we will not have the resources or motivation that are necessary to live as long as we can without dying." - Anonymous Online Contributor

"Symptoms have been used to diagnose cancer over a long period. Symptoms that indicate cancer are often poorly understood, and some may be of no use in diagnosis. It is likely that if symptoms do not correlate with the underlying disease, the patient will be reassured that they are a consequence rather than cause of their health problem. Further research should clarify the usefulness of many of those symptoms." - Anonymous Online Contributor

"Common treatments for cancer include some kind of surgery. The most common is chemotherapy (also known as "chemotherapy") that is a combination of drugs. Chemotherapy often involves a combination of several drugs: 5–10 different drugs (depending on type of cancer). In some cases the most common treatment is radiotherapy, a low-dose, high-dose, or a combination of treatment. Lastly, there is also a possibility of a combination of radiotherapy and an anti-cancer drug. Radiation therapy can be used in combination with radiation-resistant chemotherapy." - Anonymous Online Contributor

"Pemigatinib, used as the standard first line treatments for patients with advanced or metastatic EGFRvIII lung cancer, is generally well tolerated with no appreciable toxicities reported in this trial." - Anonymous Online Contributor

"The most recent published research is a mix of studies that have the most potential to affect current therapies and studies that have a great impact in the area of future prevention, diagnosis, and treatments. However, even the most recent reviews have not been conclusive, and some of the studies are far too small for conclusive conclusions." - Anonymous Online Contributor

"There is high heterogeneity in cancer staging and detection rates across countries and time; therefore, country-specific data are needed to make generalizations about the epidemiology of cancer in the world." - Anonymous Online Contributor

"As an SMC-targeting, c-Met inhibitor with a novel mode that differs from first-generation c-Met inhibitors in that it only inhibits c-Met-inactivated cells, pemigatinib has significant efficacy in reducing tumour growth in multiple preclinical models (MDA- MB-231, T44, T47D and MCF-7), although it has not produced an objective response in the clinical setting. Despite significant pharmacodynamic, dose-increasing effects on other pathways, including AKT and epidermal growth factor receptor (EGFR), it remains an attractive pre-clinical anti-tumour agent." - Anonymous Online Contributor

"Dacarbazine is commonly used to treat soft tissue sarcomas. Pemigatinib can be an option in patients with unresectable or metastatic/high-risk soft tissue sarcomas whose tumours are positive for the chimeric receptors FLT3 and c-Met. The present findings warrant a multi-institution phase III trial of pemigatinib in combination with dacarbazine in patients with unresectable or borderline resectable soft tissue sarcomas bearing in situ or unresectable or metastatic, high-risk FLT3-ITD-positive (ITD mutation present) or c-MET-positive tumour." - Anonymous Online Contributor

"When patients are informed that their cancer will be completely incurable, they tend to place less importance on physical characteristics, especially age. When patients are made aware of other treatments other than complete cure, they tend to place more value on health-related factors. The importance placed on non-physical factors by cancer patients and on physical factors by their family caregivers may be a key factor for the perception of personal control, as well as the type and amount of treatment that cancer patients receive." - Anonymous Online Contributor